Oberweis Asset Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Oberweis Asset Management’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-42,770	Closed	-$470K	–	163
2017 Q1	$470K	Sell	42,770 -27,000	-39%	-$313K	0.14%	104
2016 Q4	$945K	Buy	69,770 +14,700	+27%	+$205K	0.28%	68
2016 Q3	$678K	Buy	+55,070	New	+$649K	0.2%	85
2016 Q1	–	Sell	-96,630	Closed	-$1.67M	–	201
2015 Q4	$1.67M	Buy	96,630 +30,577	+46%	+$548K	0.47%	43
2015 Q3	$1.31M	Buy	66,053 +44,853	+212%	+$1.03M	0.38%	42
2015 Q2	$348K	Sell	21,200 -2,600	-11%	-$45.1K	0.09%	134
2015 Q1	$370K	Sell	23,800 -29,500	-55%	-$457K	0.1%	121
2014 Q4	$761K	Buy	53,300 +1,600	+3%	+$16.9K	0.23%	63
2014 Q3	$336K	Sell	51,700 -29,000	-36%	-$193K	0.09%	110
2014 Q2	$557K	Sell	80,700 -13,300	-14%	-$94K	0.14%	105
2014 Q1	$672K	Buy	94,000 +41,000	+77%	+$351K	0.14%	105
2013 Q4	$498K	Buy	+53,000	New	+$378K	0.12%	99

Other funds holding SCMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oberweis Asset Management's SCMP Position: Q2 2017 in Review

Oberweis Asset Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q2 2017, closing a stake of 42,770 shares — an estimated $470K sold.

Oberweis Asset Management first reported a position in SCMP in Q4 2013 and held it in 12 quarters. The position peaked at $1.67M in Q4 2015. 167 funds tracked by Wall St. Rank hold SCMP as of Q2 2017.

Oberweis Asset Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Oberweis Asset Management sold 42,770 Sucampo Pharmaceuticals, Inc. shares in Q2 2017, an estimated $470K.
Oberweis Asset Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2013 and held it in 12 quarters.
Oberweis Asset Management's Sucampo Pharmaceuticals, Inc. position peaked at $1.67M in Q4 2015.
167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2017.

Based on Oberweis Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.